NLRC5 and melanoma: Subsequent studies from the Kobayashi laboratory revealed that NLRC5 is inactivated in diverse cancers by a variety of genetic mechanisms including promoter methylation, copy number loss and mutations, and that the loss of NLRC5 expression correlates with reduced CTL activation and patient survival in several cancers including melanoma, bladder and cervical cancers [28].